Security record · archived quarter
CGEM
Cullinan Therapeutics, Inc. · Healthcare · Biotechnology
17Tracked holders
+1Δ holders
15.39MShares held
$91.26MReported value
+1New positions
−0Exits
Momentum inputs (comparable managers):
holder breadth +6.2% ·
share flow -3.4% ·
net new positions +5.9%
— formula
Ownership fragmentation — more holders, smaller aggregate stake
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q3 2025
Ownership over time
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 77 | +7 | 28.05M | $510.52M | +11 | −4 |
| Q1 2026 | 73 | +7 | 24.59M | $348.81M | +10 | −3 |
| Q4 2025 | 65 | +1 | 21.69M | $224.52M | +1 | — |
| Q3 2025 | 17 | +1 | 15.39M | $91.26M | +1 | — |
| Q2 2025 | 13 | 0 | 14.48M | $109.06M | +1 | −1 |
| Q1 2025 | 10 | -1 | 7.69M | $58.25M | — | −1 |
| Q4 2024 | 11 | 0 | 8.98M | $109.41M | — | — |
| Q3 2024 | 10 | +1 | 6.86M | $114.80M | +1 | — |
| Q2 2024 | 9 | — | 7.12M | $124.19M | — | — |
Who holds it · Q3 2025
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | BlackRock ✦ (passive) | 4.17M | -1.1% | $24.73M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 2 | BlackRock ✦ (passive) | 4.17M | -1.1% | $24.73M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 3 | BlackRock ✦ (passive) | 4.17M | -1.1% | $24.73M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 4 | BlackRock ✦ (passive) | 4.17M | -1.1% | $24.73M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 5 | BlackRock ✦ (passive) | 4.17M | -1.1% | $24.73M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 6 | BlackRock ✦ (passive) | 4.17M | -1.1% | $24.73M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 7 | BlackRock ✦ (passive) | 4.17M | -1.1% | $24.73M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 8 | BlackRock ✦ (passive) | 4.17M | -1.1% | $24.73M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 9 | BlackRock ✦ (passive) | 4.17M | -1.1% | $24.73M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 10 | BlackRock ✦ (passive) | 4.17M | -1.1% | $24.73M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 11 | The Vanguard Group ✦ (passive) | 2.94M | -2.5% | $17.45M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 12 | The Vanguard Group ✦ (passive) | 2.94M | -2.5% | $17.45M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 13 | The Vanguard Group ✦ (passive) | 2.94M | -2.5% | $17.45M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 14 | The Vanguard Group ✦ (passive) | 2.94M | -2.5% | $17.45M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 15 | The Vanguard Group ✦ (passive) | 2.94M | -2.5% | $17.45M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 16 | Citadel Advisors ✦ | 1.98M | -24.1% | $11.77M | 0.0% | ▼ Trim | 6 | SEC ↗ |
| 17 | Citadel Advisors ✦ | 1.98M | -24.1% | $11.77M | 0.0% | ▼ Trim | 6 | SEC ↗ |
| 18 | State Street Global Advisors ✦ (passive) | 1.68M | +4.3% | $9.95M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 19 | Geode Capital Management ✦ (passive) | 1.30M | +1.2% | $7.68M | 0.0% | ▲ Add | 6 | SEC ↗ |
| 20 | Geode Capital Management ✦ (passive) | 1.30M | +1.2% | $7.68M | 0.0% | ▲ Add | 6 | SEC ↗ |
| 21 | Goldman Sachs Group ✦ | 983.96K | — | $5.83M | 0.0% | n/c | 1 | SEC ↗ |
| 22 | Goldman Sachs Group ✦ | 983.96K | — | $5.83M | 0.0% | n/c | 1 | SEC ↗ |
| 23 | Millennium Management ✦ | 550.47K | +7.8% | $3.26M | 0.0% | ▲ Add | 5 | SEC ↗ |
| 24 | Renaissance Technologies ✦ | 529.41K | +58.3% | $3.14M | 0.0% | ▲ Add | 6 | SEC ↗ |
| 25 | Morgan Stanley ✦ | 400.15K | — | $2.37M | 0.0% | n/c | 1 | SEC ↗ |
| 26 | Morgan Stanley ✦ | 400.15K | — | $2.37M | 0.0% | n/c | 1 | SEC ↗ |
| 27 | Morgan Stanley ✦ | 400.15K | — | $2.37M | 0.0% | n/c | 1 | SEC ↗ |
| 28 | Morgan Stanley ✦ | 400.15K | — | $2.37M | 0.0% | n/c | 1 | SEC ↗ |
| 29 | Morgan Stanley ✦ | 400.15K | — | $2.37M | 0.0% | n/c | 1 | SEC ↗ |
| 30 | Morgan Stanley ✦ | 400.15K | — | $2.37M | 0.0% | n/c | 1 | SEC ↗ |
| 31 | Morgan Stanley ✦ | 400.15K | — | $2.37M | 0.0% | n/c | 1 | SEC ↗ |
| 32 | Marshall Wace ✦ | 295.44K | -52.9% | $1.75M | 0.0% | ▼ Trim | 6 | SEC ↗ |
| 33 | AQR Capital Management ✦ | 197.92K | +846.1% | $1.17M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 34 | AQR Capital Management ✦ | 197.92K | +846.1% | $1.17M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 35 | AQR Capital Management ✦ | 197.92K | +846.1% | $1.17M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 36 | AQR Capital Management ✦ | 197.92K | +846.1% | $1.17M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 37 | AQR Capital Management ✦ | 197.92K | +846.1% | $1.17M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 38 | Wellington Management ✦ | 168.13K | -9.7% | $997,017 | 0.0% | ▼ Trim | 6 | SEC ↗ |
| 39 | Wellington Management ✦ | 168.13K | -9.7% | $997,017 | 0.0% | ▼ Trim | 6 | SEC ↗ |
| 40 | Wellington Management ✦ | 168.13K | -9.7% | $997,017 | 0.0% | ▼ Trim | 6 | SEC ↗ |
| 41 | JPMorgan Chase ✦ | 63.74K | — | $377,956 | 0.0% | n/c | 1 | SEC ↗ |
| 42 | JPMorgan Chase ✦ | 63.74K | — | $377,956 | 0.0% | n/c | 1 | SEC ↗ |
| 43 | JPMorgan Chase ✦ | 63.74K | — | $377,956 | 0.0% | n/c | 1 | SEC ↗ |
| 44 | JPMorgan Chase ✦ | 63.74K | — | $377,956 | 0.0% | n/c | 1 | SEC ↗ |
| 45 | JPMorgan Chase ✦ | 63.74K | — | $377,956 | 0.0% | n/c | 1 | SEC ↗ |
| 46 | JPMorgan Chase ✦ | 63.74K | — | $377,956 | 0.0% | n/c | 1 | SEC ↗ |
| 47 | JPMorgan Chase ✦ | 63.74K | — | $377,956 | 0.0% | n/c | 1 | SEC ↗ |
| 48 | JPMorgan Chase ✦ | 63.74K | — | $377,956 | 0.0% | n/c | 1 | SEC ↗ |
| 49 | Two Sigma Investments ✦ | 59.67K | New | $353,855 | 0.0% | New | 1 | SEC ↗ |
| 50 | T. Rowe Price ✦ | 43.24K | +18.7% | $257,000 | 0.0% | ▲ Add | 6 | SEC ↗ |
| 51 | D. E. Shaw & Co. ✦ | 25.62K | +1.1% | $151,921 | 0.0% | ▲ Add | 6 | SEC ↗ |
| 52 | Fidelity (FMR) ✦ | 968 | -74.6% | $5,740 | 0.0% | ▼ Trim | 2 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value — the conviction measure. ✦ = curated manager.
New buyers
| Two Sigma Investments | $353,855 | 0.0% |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 172 holders, 65.27M shares, $895.39M reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
Frequently co-owned
What else this security's tracked holders most often hold — shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Aug 13
Michaelson Jennifer
Officer · 30.00K sh · $607,800
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology
Aug 14
SC 13G/A — BIOTECHNOLOGY VALUE FUND L P
Aug 14
SC 13G — PRICE T ROWE ASSOCIATES INC /MD/
Aug 07
SC 13G — STATE STREET CORP
Provenance: Ownership from parsed 13F common-stock positions (tracked universe, comparable sets for changes); insider rows from Forms 3/4/5; stakes from Schedules 13D/13G; every filing links to its original on SEC EDGAR.
Reporting period: Q3 2025 ·
Methodology ·
Get this via the API